Madrigal Pharmaceuticals announced that the Company’s Marketing Authorization Application, MAA, for resmetirom for the treatment of NASH/metabolic dysfunction-associated steatohepatitis, MASH, with liver fibrosis has been validated and is now under evaluation with the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP. “NASH with fibrosis represents a serious burden for both patients and health systems. Without treatment, the disease can lead to cirrhosis, liver failure, liver cancer and premature death,” said Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal. “Based on the positive results from our Phase 3 MAESTRO trials, we believe resmetirom has the potential to become the first therapy for patients with NASH with liver fibrosis to receive approval in Europe.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $320 from $300 at Oppenheimer
- Madrigal Pharmaceuticals appoints Mardi Dier as CFO
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Madrigal Pharmaceuticals reports Q4 EPS ($5.68), consensus ($5.28)
- Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer